Abstract
Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria®, AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia. Therefore, several countries have recommended replacing the second dose of ChAdOx1 nCoV-19 with an mRNA-based vaccine as a precautionary measure, although data on safety and efficacy of such heterologous prime-boost regimen are sparse. Therefore, vaccinees, who had received a heterologous vaccination using ChAdOx1 nCoV-19 as prime and BNT162b2 (Comirnaty®, BioNTech-Pfizer) mRNA as boost vaccination were offered SARS-CoV-2 antibody testing to quantify their vaccine-induced neutralizing antibody response5. The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime. In our cohort comprising over 480 individuals, the heterologous vaccination scheme induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination. This proves that a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection, and may even increase vaccine efficacy offering an alternative in a setting of vaccine shortage.
Competing Interest Statement
The authors declare no conflict of interest concerning the results reported here. Outside of the study, UP received grants from ALIOS and VirBio and personal fees from Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sobi, and Vaccitech. UP is co-founder and share-holder of SCG Cell Therapy. OAC received grants from Janssen, grants and personal fees from Merck/MSD, grants and personal fees from Pfizer, outside the submitted work.
Funding Statement
Funded by the German Centre for Infection Research (DZIF), the European Union's "Horizon 2020 Research and Innovation Programme" under grant agreement No. 101037867 (VACCELERATE), the "Bayerisches Staatsministerium fuer Wissenschaft und Kunst" for the CoVaKo-2021 and the For-COVID projects and the Helmholtz Association via the collaborative research program "CoViPa". Further support was obtained from the Federal Ministry of Education and Science (BMBF) through the "Netzwerk Universitaetsmedizin", project "B-Fast", and the Bavarian Research Foundation via project "CoV-Rapid"
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The retrospective analysis plan on the comparison of the SARS-CoV-2 antibody levels in response to different vaccine regimens was approved by the local ethics committees in Erlangen (Az. 202_21 Bc) and Munich (Az. 26/21 und Az. 330/21 S).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Study team (to be listed in PubMed) University Hospital rechts der Isar, Technical University of Munich: Hedwig Roggendorf, Otto Zelger, Catharina Christa.
University Hospital of Cologne: Sarah Heringer.
University Hospital Erlangen: Rayya Alsalameh, Jan Esse, Jochen Mattner, Monika Wytopil.
Transparency declaration The authors declare no conflict of interest concerning the results reported here.
Outside of the study, UP received grants from ALIOS and VirBio and personal fees from Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sobi, and Vaccitech. UP is co-founder and share-holder of SCG Cell Therapy. OAC received grants from Janssen, grants and personal fees from Merck/MSD, grants and personal fees from Pfizer, outside the submitted work.
Data Availability
We share data if reasonable requests are received. Requests should be directed to the corresponding author at protzer@tum.de
